4Kastritis E, Wechalekar AD, Dimopoulos MA, et al. Bortezomib with or without dexamethasone in primary systemic (light chain )amyloidosis.J ClinOncol,2010,28 : 1031-1037.
5Reece DE, Hegenbart U, Sanchorawala V. Efficacy and safety of once- weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood, 2011,118 : 865- 873.
6Adam Z, Pour L, Krejci M, et al. Treatment of AL-amyloidosis-results from one elinie and review of published experience with new agents( bort- ezomib, thalidomide and lenalidomide )in AL-amyloidosis. Vnitr Lek, 2010,56 : 190-209.
7Comenzo RL. How I treat amyloidosis. Blood,2009,114:3147-3157.
8Cibeira MT, Sanchorawala V, Seldin DC, et al. Outcome of AL amyloid- osis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood, 2011,118: 4346- 4352.
9Qu Z, Zheng X, Wang SX, et al. Clinical and pathological features of renal amyloidosis : an analysis of 32 patients in a single Chinese eentre. Neph- rology (Carlton) ,2010,15 : 102-107.
10Feng D, Syed IS, Martinez M, et al. Intracardiac thrombosis and antico- agulation therapy in cardiac amyloidosis. Circulation, 2009,119 : 2490- 2497.
4Mitsuyo Itabashi,Takashi Takei,Misao Tsukada,Hidekazu Sugiura,Keiko Uchida,Ken Tsuchiya,Kazuho Honda,Kosaku Nitta.Association between clinical characteristics and AL amyloid deposition in the kidney[J].Heart and Vessels.2010(6)
